Relay Therapeutics (NASDAQ:RLAY) reported quarterly losses of $(0.41) per share which missed the analyst consensus estimate of $(0.37) by 10.81 percent. This is a 10.87 percent increase over losses of $(0.46) per share from the same period last year. The company reported quarterly sales of $3.000 million which beat the analyst consensus estimate of $2.560 million by 17.19 percent. This is a 60.93 percent decrease over sales of $7.679 million the same period last year.